KugelOne™
THE PRECISION INSTRUMENT
For Manufacturer Discount Program Compliance
The IRA has created a landscape of regulatory toxicity. KugelOne is the specialized intelligence engine designed to navigate the Manufacturer Discount Program with surgical precision.
Every output source-traced. Every conclusion auditable. Every citation verbatim.
We call it Whitebox AI
The Liability Paradox
Why the Manufacturer Discount Program is a Multi-Million Dollar Precision Exercise
The IRA's Manufacturer Discount Program isn't just complex — it's binary. A single misinterpretation of phase-in rules, OOP cap dynamics, or TPA invoice logic doesn't just reduce your margin — it can trigger an accrual cliff that erases your projected net price entirely.
For a mid-sized specialty portfolio, the difference between “correct” and “almost correct” is measured in tens of millions of dollars in annual GTN exposure.
Three Ways a Compliance Oversight Becomes a Financial Catastrophe
The Phase-In “Cliff”
The Catastrophic Acceleration
The TPA “True-Up” Trap
Don't leave your GTN to chance. You need a Regulatory Intelligence Engine to resolve complexities faster.
THE COMPLIANCE DIFFERENCE
Architected for Defensibility
WHAT YOU GET
Every Output is a Defensible Document
Unlike generic AI chatbots that produce unverifiable prose, every KugelOne response is a structured, traceable compliance artifact.
Every claim maps to a specific section of statutory text, CMS guidance, or CFR regulation. No hallucinated references.
Source passages are included verbatim so your compliance team can verify the AI's reasoning against the original text.
Each response identifies financial exposure risks, compliance deadlines, and penalty thresholds relevant to your specific question.
Download professional-grade reports with a built-in AI disclosure statement, ready for board review or external audit submission.
THE SHIFT
From Black Box to Whitebox
- • Generates plausible-sounding but unverifiable answers
- • No source traceability—impossible to audit
- • Hallucinates regulatory citations and CFR references
- • Generic model with no MDP-specific training
- • Your data may be used to train third-party models
- • Still requires outside counsel to validate every output
- • Every answer backed by numbered, verbatim citations
- • Full source-path traceability for legal defensibility
- • Grounded exclusively in authoritative CMS and IRA sources
- • Purpose-built for MDP phase-ins, OOP caps, and TPA logic
- • Your data is never stored, never retained, never used for training
- • Outputs are audit-ready, reducing external counsel dependency
THE WHITEBOX REPORT
Your Compliance Team's New Standard
Every query generates a formal Q&A Export with Source-Path Traceability—a professional-grade document your legal and compliance teams can trust without additional verification overhead.
- Structured analysis mapped to your specific questions
- Numbered citations with document paths
- Verbatim excerpts from source regulations
- Financial exposure and penalty risk quantification
- AI disclosure statement for compliance governance
- PDF export for board and audit committee review
Real Questions. Real Answers.
These are example outputs from KugelOne's compliance intelligence engine.
Turnaround times are typical; complex cases may require additional analysis.
“Our company meets the definition of a 'Specified Manufacturer' for 2025 because our 2021 Part D sales were below the statutory threshold. However, we do not qualify as a 'Specified Small Manufacturer.' Does the discount phase-in (starting at 1% in 2025) apply to all of our Part D claims, or is it limited to a specific beneficiary population?”
KugelOne Analysis:
Under the Medicare Part D Manufacturer Discount Program (MDP), the discount phase-in for a “Specified Manufacturer” is not applied to all Part D claims. Instead, it is strictly limited to applicable drugs dispensed to applicable beneficiaries who are eligible for a Low-Income Subsidy (LIS) under section 1860D-14(a) of the Act.
For all other Part D beneficiaries (non-LIS enrollees), a Specified Manufacturer that does not qualify as a “Specified Small Manufacturer” must provide the full statutory discount amounts starting January 1, 2025.
Compliance Audit & Financial Exposure Risks:
- Beneficiary Population Restriction: The phase-in schedule (starting at 1% in 2025 and 2% in 2026) applies only to LIS-eligible individuals.
- Specified Small Manufacturer Distinction: Only manufacturers qualifying as “Specified Small Manufacturers” receive a phase-in for all applicable beneficiaries.
- Eligibility Requirement: To maintain this status, the drug must have been marketed as of August 16, 2022.
“Under the 2025 Part D benefit structure, does a beneficiary's participation in the Medicare Prescription Payment Plan (M3P) delay the onset of the Catastrophic Phase? Specifically, if a patient incurs $2,000 in OOP costs in January but pays over 12 months, does the manufacturer's liability for the 20% catastrophic discount begin in January or later?”
KugelOne Analysis:
Under the 2025 Part D benefit structure, a beneficiary's participation in the Medicare Prescription Payment Plan (M3P) does not delay the onset of the Catastrophic Phase or the timing of manufacturer liability for the 20% catastrophic discount.
1. Timing of Catastrophic Phase Onset
The Catastrophic Phase begins immediately once an enrollee has incurred costs that equal or exceed the annual out-of-pocket (OOP) threshold, which is set at $2,000 for 2025.
2. Manufacturer Liability Timing
Manufacturer liability under the MDP is triggered by the date of service and the beneficiary's status at the time the drug is dispensed.
Time-to-Evidence: From Billable Weeks to Actionable Minutes
The Medicare Part D Manufacturer Discount Program (MDP) is not just a list of rules — it is a complex web of interacting statutes, IRS tax codes, and operational guidance. Answering a single strategic question often requires weeks of cross-functional meetings, external legal opinions, and manual financial modeling.
The KugelOne Regulatory Engine changes the physics of compliance. Instead of retrieving simple facts, it executes complex logic chains — reducing your Time-to-Evidence from weeks to actionable minutes while maintaining audit-grade precision.
The Question
We have identified a high volume of claims originating from 340B covered entities. Under the Final MDP Guidance, are 340B claims considered 'Applicable Drugs' subject to the manufacturer discount?
KugelOne Analysis
Under the Medicare Part D Manufacturer Discount Program (MDP) effective January 1, 2025, claims originating from 340B covered entities are considered “applicable drugs” subject to manufacturer discounts if they meet the statutory criteria.
The Question
We are calculating our liability for 2025. Our Wholesaler Agreements include 'Bona Fide Service Fees' for distribution and separate 'Data Fees' for inventory reporting. Can these fees be deducted from the price used to calculate the 10% discount?
KugelOne Analysis
Under the MDP effective January 1, 2025, the manufacturer discount is calculated based on the negotiated price as defined in 42 CFR § 423.100. Bona Fide Service Fees and Data Fees paid to wholesalers are not deductible from the negotiated price for discount calculation purposes.
The Question
Our parent company holds a 45% equity stake in a Joint Venture (JV) that sells a separate Part D portfolio. Does this 45% ownership trigger the 'Aggregation Rule' under IRC Section 52(a) or (b) as referenced in the IRA?
KugelOne Analysis
Under the MDP, the “Aggregation Rule” for determining eligibility for the “Specified Small Manufacturer” phase-in is governed by Social Security Act Section 1860D-14C(g)(4). The applicable threshold under IRC Section 52(b) is “more than 50 percent.” Since your parent holds 45%, aggregation is not triggered.
Curated Regulatory Knowledge Base
KugelOne is grounded in authoritative sources — not the general internet. Every answer traces back to official CMS guidance, statutory text, and regulatory publications.
- IRA statutory text (SSA § 1860D-14C)
- CMS Final Rules and sub-regulatory guidance
- MTF Technical Specifications
- Updated within 48 hours of new CMS publications
Professional-Grade Citation Reports
Every query generates a formal Q&A Export with Source-Path Traceability, providing your legal and compliance teams with the verbatim excerpts needed for final verification.
- Structured analysis mapped to your specific questions
- Numbered citations with document paths
- Verbatim excerpts from source regulations
- PDF export for legal team review
The Science of Certainty
From complex statutory text to actionable compliance decisions.
Target
Identify the specific statutory provisions affecting your portfolio.
Analyze
Model phase-in impacts and liabilities across your full portfolio.
Resolve
Generate audit-ready memos and strategic recommendations.
KugelOne Capabilities
Regulatory Intelligence Engine
Instant, semantic search across thousands of pages of IRA statutes.
- Context-aware Search
- Citation Verification
- Multi-document Synthesis
MDP Liability Modeling
Specifically designed to calculate liabilities under the Manufacturer Discount Program, accounting for all transition periods and phase-ins.
- Phase-in rate calculations (CY2025-2028)
- OOP cap impact modeling
- M3P adherence adjustments
- Catastrophic phase timing